dr. hong on the mechanism of action of tisotumab vedotin in cervical cancer
Published 5 years ago • 857 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
0:55
dr. monk on the mechanism of action of tisotumab vedotin in recurrent cervical cancer
-
1:45
dr. hong on the safety profile of tisatumab vedotin in cervical cancer
-
0:57
dr. monk on the utility of tisotumab vedotin in recurrent cervical cancer
-
1:12
dr. monk on the importance of pap testing in cervical cancer
-
8:52
frontline therapies for metastatic cervical cancer
-
1:45
dr. coleman on the clinical implications of the innovatv 204 trial in cervical cancer
-
2:09
dr. leath on agents under investigation in cervical cancer
-
1:16
dr. rischin discusses the future of cemiplimab in cervical cancer
-
1:36
dr. ferguson on the impact of the lacc trial data on cervical cancer surgery
-
0:59
dr. monk discusses the role of bevacizumab in metastatic cervical cancer
-
1:47
dr. leath on the results of the gog 240 trial in advanced cervical cancer
-
2:47
antibody drug conjugates for ovarian cancer
-
0:54
dr. salani on the current state of biomarker testing in cervical cancer
-
1:16
dr. coleman on the use of immunotherapy in cervical cancer
-
5:08
challenges with ngs for trk inhibition
-
2:08
dr. ginsburg discusses cervical cancer screening techniques
-
6:17
optimal use of ngs for trk inhibition
-
0:42
dr. rischin discusses role of cemiplimab in cervical cancer
-
4:09
moving forward with trk inhibition